Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals

Liu, Chen-Hua; Chang, Yu-Ping; Fang, Yu-Jen; Cheng, Pin-Nan; Chen, Chi-Yi; Kao, Wei-Yu; Lin, Chih-Lin; Yang, Sheng-Shun; Shih, Yu-Lueng; Peng, Cheng-Yuan; Tsai, Ming-Chang; Huang, Shang-Chin; Su, Tung-Hung; Tseng, Tai-Chung; Liu, Chun-Jen; Chen, Pei-Jer; Kao, Jia-Horng

doi:10.1007/s00535-024-02101-2

J Gastroenterol

2024

DOI: 10.1007/s00535-024-02101-2

|View full text |Cite

Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals

Chen-Hua Liu,

Yu-Ping Chang,

Yu-Jen Fang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection

Liu,

Cheng,

Fang

et al. 2024

Journal of Hepatology

View full text Add to dashboard Cite

Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection

Liu,

Cheng,

Fang

et al. 2024

Journal of Hepatology

View full text Add to dashboard Cite

The Impact of Liver Steatosis on Interleukin and Growth Factors Kinetics during Chronic Hepatitis C Treatment

Radmanic Matotek,

Zidovec-Lepej,

Salek

et al. 2024

JCM

View full text Add to dashboard Cite

Background/Objectives: Various biological response modifiers play important roles in the immunopathogenesis of chronic hepatitis C (CHC). While serum levels of cytokines and growth factors change with the disease severity and treatment responses, the impact of concomitant liver steatosis on systemic inflammatory response is largely unknown. The aim of this study was to analyze the characteristics and kinetics of serum profiles of interleukins and growth factors in CHC patients with steatotic liver disease (SLD). Methods: Serum concentrations of 12 cytokines (IL-5, IL-13, IL-2, IL-6, IL-9, IL-10, IFN-γ, TNF-α, IL-17A, IL-17F, IL-4 and IL-22) and 6 growth factors (Angiopoietin-2, EGF, EPO, HGF, SCF, VEGF) were analyzed in 56 CHC patients at four time points (baseline, week 4, week 8 and SVR12) with bead-based flow cytometry assay. Results: At baseline, patients with SLD had significantly lower IL-9, IL-10, IL-13 and IL-22 and higher serum concentrations of EGF, VEGF and ANG. In a subgroup of patients with advanced liver fibrosis, SLD was linked with lower serum concentrations of IL-4, IL-5, IL-9, IL-10, IL-13 and IL-22 and higher concentrations of HGH and VEGF. Distinct cytokine kinetics during DAA treatment was observed, and SLD was identified as the main source of variation for IL-5, IL-9, IL-10, IL-13, IL-17A, IL-22, EGF, VEGF and ANG. Patients with SLD at SVR12 had significantly higher VEGF and HGF serum concentrations. Conclusions: SLD is associated with distinct cytokine and growth factor profiles and kinetics during CHC treatment, which might be associated with disease severity and the capacity for liver regeneration and contribute to fibrosis persistence.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals

Cited by 2 publications

References 48 publications

Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection

Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection

The Impact of Liver Steatosis on Interleukin and Growth Factors Kinetics during Chronic Hepatitis C Treatment

Contact Info

Product

Resources

About